Pacific Biosciences
PACB
101 hedge funds and large institutions have $193M invested in Pacific Biosciences in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 48 increasing their positions, 20 reducing their positions, and 18 closing their positions.
140% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 20
4.89% more ownership
Funds ownership: 66.99% → 71.88% (+4.9%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less capital invested
Capital invested by funds: $206M → $193M (-$13M)
7% less funds holding
Funds holding: 109 → 101 (-8)
44% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 18
86% less call options, than puts
Call options by funds: $57K | Put options by funds: $409K
Top Buyers
| 1 |
CCM
Consonance Capital Management
New York
|
+$14.3M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$10.6M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$5.63M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.45M |
| 5 |
Blackstone Inc
New York
|
+$4.45M |
Top Sellers
PACB Hedge Fund Activity: Q1 2018 in Review
101 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q1 2018, worth a combined $193M — down 6.3% from $206M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of PACB and 10 opened new positions — a net loss of 8 holders — while 20 trimmed existing stakes and 48 added.
The largest buyer was Consonance Capital Management, adding an estimated $14.3M. The largest seller was Invesco, cutting an estimated $10.7M.
- 101 institutional investors held Pacific Biosciences (PACB) as of Q1 2018, down from 109 in Q4 2017.
- Funds reported $193M of Pacific Biosciences stock for Q1 2018, down 6.3% quarter-over-quarter.
- 10 funds opened new Pacific Biosciences positions in Q1 2018 and 18 closed out, a net change of -8 holders.
- The largest Pacific Biosciences buyer in Q1 2018 was Consonance Capital Management, an estimated $14.3M added.
- The largest Pacific Biosciences seller in Q1 2018 was Invesco, an estimated $10.7M sold.
Based on aggregated 13F filings for Q1 2018.